Fox Business - The Power to Prosper
Search Site

Novo Nordisk

Related Topics

  1. Mid Cap
  2. Merck
  3. Bristol-Myers Squibb
  4. Eli Lilly
  5. Mutual Funds
  6. A&P
Get updates on Novo Nordisk
Novo Nordisk Net Profit Up As Insulin Sales Surge

Denmark's Novo Nordisk A/S (NOVO-B.KO), the world's largest maker of insulin, Wednesday posted a forecast-beating first-quarter net profit rise of 28%, helped by strong growth in sales of its diabetes drug Victoza, and raised its full-year outlook slightly.MAIN FACTS:-Lifts 2013 sales growth outlook slightly to 9%-11% in local currencies, from 8%-11%, while reported sales growth is now expected to be around 3 percentage points lower than growth measured in local currencies having earlier expected the figure to be 4.5 percentage points lower.-Operating profit growth is still seen at around 10%, but the reported operating profit growth is now expected to be around 5 percentage points lower than growth measured in local currencies, from a previous estimate of around 7 percentage points lower.-Now sees FY net financials income of around DKK900 million, from previous estimate of DKK1.4 billion.-Still see FY capex at around DKK3.5 billion.-CEO Lars Rebien Sorensen says: "We are pleased with ...

Read More ›

  1. Nasdaq Shares Hit New Annual High

    FBN’s Lauren Simonetti breaks down the day in the markets.

  2. EUROPE MARKETS: Novo Nordisk Leads Europe Lower After FDA News

    Novo Nordisk AS on Monday knocked the air out of Europe's benchmark stock index after a setback in the U.S., while the region's bourses saw mixed trade as a meeting ...

  3. EUROPE MARKETS: Novo Nordisk Slams Europe Stocks After FDA News

    Novo Nordisk AS on Monday knocked the air out of Europe's benchmark stock index after a setback in the U.S., while the region's other bourses traded mixed ahead of a...

  4. Novo Nordisk Shares Slide on FDA Letter

    Shares of Novo Nordisk (NYSE:NVO) fell more than 13% on Monday morning after the diabetes-focused drug maker said its new, highly-anticipated insulin drugs Tresiba a...

  5. Denmark ETF Decked by Novo Nordisk's Slide

    Shares of the rarely discussed iShares MSCI Denmark Capped Investable Market Index Fund (BATS: EDEN) are off by 3.2 percent Monday in what is shaping up to be one of...

  6. Novo Nordisk Stung by FDA Data Request

    Novo Nordisk A/S (NVO) said U.S. regulators have asked for additional testing on its hotly anticipated Tresiba insulin products, which could lead to a delay of the d...

  7. EUROPE MARKETS: Europe Stocks Waver, Novo Nordisk Off On FDA News

    European stock markets showed mixed moves on Monday, with heavyweight oil firms tracking oil prices lower and Novo Nordisk AS sinking U.S. regulators failed to clear...

  8. Novo Nordisk Sinks 14% On Disappointing Drug News

    Shares of Novo Nordisk AS sank 14% in European trading on Monday. In a statement the prior day, the Danish drugmaker said the Danish drugmaker said the U.S. Food and...

  9. Novo Nordisk Outlook Bouyed by Tresiba Launch, Insulin Demand

    Novo Nordisk A/S (NVO), the world's largest maker of insulin, Thursday posted a substantial rise in quarterly profit due to strong sales of diabetes drugs and said i...

  10. EUROPE MARKETS: Europe Shares Struggle On Growth Fears

    Concerns over global economic growth and a continuing political impasse surrounding the U.S. budget left European shares struggling for direction Wednesday.The Stoxx...

  11. ADR Shares End Mixed; Metals, Mining Stocks Fall on China Inflation Report

    International companies trading in New York closed mixed Friday, hurt by lower metals and mining shares after downbeat news from top industrial metal consumer China....

  12. EUROPE MARKETS: Europe Trades Sideways With U.S., China In Focus

    European equities saw a mixed trading session on Friday, moving sideways as investors focused on earnings season in the U.S. and worries that accelerating Chinese in...

  1. Mexico Hit With a Spike in Diabetes Cases

    An alarming number of Mexicans are being diagnosed with diabetes, making the country a priority market for tackling a disease that is exploding in developing countri...

  2. FDA Conducting Safety Review Of Certain Diabetes Drugs

    The U.S. Food and Drug Administration Thursday said it is reviewing information about a class of diabetes drugs that suggests they might cause pre-cancerous changes ...

  3. For Nordic bosses, joys of home trump top dollar pay

    Executive excess need not be etched in stone. Just look at the Nordic region, where an egalitarian tradition and a high quality of life leave top managers content wi...

  4. These ETFs Have Moving Average Problems

    Let's quickly clear up that headline. Not all of the ETFs that will be highlighted here have violated a key moving average such as the 50- or 200-day lines.However, ...

  5. Glaxo Research Chief Looks Ahead to Next Wave of New Medicines

    UPPER MERION, Pa.--Drug maker GlaxoSmithKline PLC (GSK, GSK.LN) is keeping regulators busy with six new drug applications under review but 2013 also is shaping up as...

  6. Novo Nordisk Launches Drug, Device for Haemophilia Patients

    Denmark's Novo Nordisk A/S (NOVO-B.KO), the world's largest maker of insulin, said Friday it has launched its NovoSeven drug with a pre-filled syringe that will supp...

  7. ADR Shares Close Mixed As Novo Nordisk Drops On FDA News

    International companies trading in New York closed mixed Monday, as Novo Nordisk AS (NVO, NOVO-B.KO) led European stocks lower, while most Asian markets were closed ...

‹ Prev1234Next ›
Freebase CC-BY
Source: Novo Nordisk on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL